Search 

Trespa is Top building material supplier and provide scientific surface solutions to laboratory environment. Our client includes Roche, BI, AZ, Pfizer, QiLu Pharma, Innocare , BASF etc

A publicly-traded bioceutical research, development and marketing firm with over 40 products backed by a combined $68 million in research and development and clinical studies. TRICCAR solutions support health challenges affecting over 6 billion people worldwide, beginning with four products to be introduced in 2021:

AVL™ - Antiviral immunity support
Global audience size: 6.2+ billion

CAL™ - Calcium deficiency
Global audience size: 6+ billion

OFF™ - Weight and obesity management
Global audience size: 1+ billion

CLM™ - Menopausal support
Global audience size: 500+ million

Having met 85%> effectiveness in placebo-based, double-blind studies, TRICCAR’s products are ready for market introduction as over-the-counter, direct-to-consumer bioceutical products. An additional 8 products will undergo Food and Drug Administration (FDA) approval. Our initial four products are targeted towards women, ages 25-65, yet appeal to all demographics and genders.

We sell via our patented and patent-pending direct-to-consumer marketing technologies that have historically generated $18 in revenue for every $1 spent compared to industry averages of $2 for every $1 spent. We add to these efforts with retail (ex. Walgreens, CVS, COSTCO, etc.) and online marketplaces (ex. Walmart.com, Amazon.com), and a 130,000 physician/chiropractor network.

Our Series B Convertible Preferred PIPE offering minimizes investor risk while providing significant potential upside. TRICCAR anticipates 3-year total revenue to exceed $163.2 million. Based on comparable price/sales valuations, this could indicate a market cap of approximately $403.5 million at time of conversion.

TIF is a VC investor specializing in early stage biotech companies in China.

an investment bank in shanghai

TusPark UK is a science and technology service corporation with an investment arm as a venture capital and private equity group fund. TusPark UK has invested £250M+ in Cambridge since 2018 (e.g. the landmark joint venture with the Trinity College to develop and operate TusPark Cambridge Science Park), and its investment portfolio spans in the era of life science/healthcare, digital technologies (big data, AI and IoT, etc.), new material, and environmental & new energy, with a unique model of "Incubation + Investment + M&As".